Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chua, 2015, Complement factor C4d is a common denominator in thrombotic microangiopathy, J Am Soc Nephrol, 26, 2239, 10.1681/ASN.2014050429
Hou, 2014, Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney Int, 85, 450, 10.1038/ki.2013.340
Larsen, 2014, Membranous-like glomerulopathy with masked IgG kappa deposits, Kidney Int, 86, 154, 10.1038/ki.2013.548
Larsen, 2015, Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits, Kidney Int, 88, 867, 10.1038/ki.2015.195
Cook, 2015, C4d staining in the diagnosis of C3 glomerulopathy, J Am Soc Nephrol, 26, 2609, 10.1681/ASN.2015040433
Sethi, 2015, C4d as a diagnostic tool in proliferative GN, J Am Soc Nephrol, 26, 2852, 10.1681/ASN.2014040406
West, 2001, Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2, Am J Kidney Dis, 37, 1120, 10.1053/ajkd.2001.24511
Sethi, 2012, C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up, Kidney Int, 82, 465, 10.1038/ki.2012.212
Sethi, 2009, Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway, Kidney Int, 75, 952, 10.1038/ki.2008.657
Loirat, 2016, An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, 31, 15, 10.1007/s00467-015-3076-8
Caprioli, 2006, Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome, Blood, 108, 1267, 10.1182/blood-2005-10-007252
Kavanagh, 2013, Atypical hemolytic uremic syndrome, Semin Nephrol, 33, 508, 10.1016/j.semnephrol.2013.08.003
Sansbury, 2014, Factors determining penetrance in familial atypical haemolytic uraemic syndrome, J Med Genet, 51, 756, 10.1136/jmedgenet-2014-102498
Bresin, 2013, Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, 24, 475, 10.1681/ASN.2012090884
Servais, 2012, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, 82, 454, 10.1038/ki.2012.63
Fervenza, 2012, Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis, Am J Kidney Dis, 60, 126, 10.1053/j.ajkd.2012.03.007
Sandhu, 2012, C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis, Am J Kidney Dis, 60, 1039, 10.1053/j.ajkd.2012.04.032
Vernon, 2012, Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency, Am J Kidney Dis, 60, 121, 10.1053/j.ajkd.2012.02.329
Yu, 2014, Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration, Hum Mol Genet, 23, 5283, 10.1093/hmg/ddu226
Kavanagh, 2015, Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels, Hum Mol Genet, 24, 3861
Recalde, 2016, Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases, J Am Soc Nephrol, 27, 1305, 10.1681/ASN.2015050580
Misra, 2004, Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature, Medicine (Baltimore), 83, 18, 10.1097/01.md.0000111061.69212.59
Dalvin, 2016, Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III, Retin Cases Brief Rep, 10, 72, 10.1097/ICB.0000000000000164
Duvall-Young, 1989, Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report, Br J Ophthalmol, 73, 297, 10.1136/bjo.73.4.297
Mathieson, 1993, Complement-mediated adipocyte lysis by nephritic factor sera, J Exp Med, 177, 1827, 10.1084/jem.177.6.1827
Fritsche, 2013, Seven new loci associated with age-related macular degeneration, Nat Genet, 45, 433, 10.1038/ng.2578
Gerber, 2002, Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study, J Infect Dis, 186, 493, 10.1086/341940
Angioi, 2016, Diagnosis of complement alternative pathway disorders, Kidney Int, 89, 278, 10.1016/j.kint.2015.12.003
Zuber, 2012, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, 8, 643, 10.1038/nrneph.2012.214
Bu, 2016, High-Throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies, J Am Soc Nephrol, 27, 1245, 10.1681/ASN.2015040385
de Cordoba, 2016, Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations, Immunobiology, 221, 709, 10.1016/j.imbio.2015.05.015
Noris, 2003, Familial haemolytic uraemic syndrome and an MCP mutation, Lancet, 362, 1542, 10.1016/S0140-6736(03)14742-3
Richards, 2003, Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome, Proc Natl Acad Sci U S A, 100, 12966, 10.1073/pnas.2135497100
Ault, 1997, Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism, J Biol Chem, 272, 25168, 10.1074/jbc.272.40.25168
Levy, 1986, H deficiency in two brothers with atypical dense intramembranous deposit disease, Kidney Int, 30, 949, 10.1038/ki.1986.278
Martinez-Barricarte, 2010, Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation, J Clin Invest, 120, 3702, 10.1172/JCI43343
Montes, 2008, Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis, Mol Immunol, 45, 2897, 10.1016/j.molimm.2008.01.027
Schejbel, 2011, Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation, Genes Immun, 12, 90, 10.1038/gene.2010.63
Abarrategui-Garrido, 2009, Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome, Blood, 114, 4261, 10.1182/blood-2009-05-223834
Delvaeye, 2009, Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, 361, 345, 10.1056/NEJMoa0810739
Fremeaux-Bacchi, 2013, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, 8, 554, 10.2215/CJN.04760512
Lemaire, 2013, Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, 45, 531, 10.1038/ng.2590
Maga, 2010, Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome, Hum Mutat, 31, E1445, 10.1002/humu.21256
Esparza-Gordillo, 2005, Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32, Hum Mol Genet, 14, 703, 10.1093/hmg/ddi066
Challis, 2016, A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome, J Am Soc Nephrol, 27, 1617, 10.1681/ASN.2015010100
Chen, 2014, Complement factor H-related hybrid protein deregulates complement in dense deposit disease, J Clin Invest, 124, 145, 10.1172/JCI71866
Gale, 2010, Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis, Lancet, 376, 794, 10.1016/S0140-6736(10)60670-8
Tortajada, 2013, C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation, J Clin Invest, 123, 2434, 10.1172/JCI68280
Valoti, 2015, A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation, J Am Soc Nephrol, 26, 209, 10.1681/ASN.2013121339
Venables, 2006, Atypical haemolytic uraemic syndrome associated with a hybrid complement gene, PLoS Med, 3, e431, 10.1371/journal.pmed.0030431
Athanasiou, 2011, Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees, Clin J Am Soc Nephrol, 6, 1436, 10.2215/CJN.09541010
Chauvet, 2016, A familial C3GN secondary to defective C3 regulation by complement receptor 1 and factor H, J Am Soc Nephrol, 27, 1665, 10.1681/ASN.2015040348
Noris, 2013, Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation, Curr Opin Nephrol Hypertens, 22, 704, 10.1097/MNH.0b013e328365b3fe
Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30
Frimat, 2013, Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome, Blood, 122, 282, 10.1182/blood-2013-03-489245
Goicoechea de Jorge, 2007, Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc Natl Acad Sci U S A, 104, 240, 10.1073/pnas.0603420103
Manuelian, 2003, Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome, J Clin Invest, 111, 1181, 10.1172/JCI16651
Marinozzi, 2014, Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?, J Am Soc Nephrol, 25, 2053, 10.1681/ASN.2013070796
Noris, 2014, Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, 124, 1715, 10.1182/blood-2014-02-558296
Perez-Caballero, 2001, Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome, Am J Hum Genet, 68, 478, 10.1086/318201
Roumenina, 2009, Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome, Blood, 114, 2837, 10.1182/blood-2009-01-197640
Sanchez-Corral, 2002, Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome, Am J Hum Genet, 71, 1285, 10.1086/344515
Schramm, 2015, Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome, Blood, 125, 2359, 10.1182/blood-2014-10-609073
Stahl, 2008, Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation, Blood, 111, 5307, 10.1182/blood-2007-08-106153
Bernabeu-Herrero, 2015, Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome, Mol Immunol, 67, 276, 10.1016/j.molimm.2015.06.021
Caprioli, 2003, Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease, Hum Mol Genet, 12, 3385, 10.1093/hmg/ddg363
Harris, 2012, The complotype: dictating risk for inflammation and infection, Trends Immunol, 33, 513, 10.1016/j.it.2012.06.001
Pickering, 2007, Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains, J Exp Med, 204, 1249, 10.1084/jem.20070301
Noris, 2010, Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, 5, 1844, 10.2215/CJN.02210310
Sanchez Chinchilla, 2014, Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, 9, 1611, 10.2215/CJN.01640214
Abrera-Abeleda, 2011, Allelic variants of complement genes associated with dense deposit disease, J Am Soc Nephrol, 22, 1551, 10.1681/ASN.2010080795
Goicoechea de Jorge, 2013, Dimerization of complement factor H-related proteins modulates complement activation in vivo, Proc Natl Acad Sci U S A, 110, 4685, 10.1073/pnas.1219260110
Licht, 2006, Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II), Kidney Int, 70, 42, 10.1038/sj.ki.5000269
Wong, 2014, Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN, J Am Soc Nephrol, 25, 2425, 10.1681/ASN.2013070732
Legendre, 2013, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, 368, 2169, 10.1056/NEJMoa1208981
Mannucci, 2015, The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring, Thromb Res, 136, 851, 10.1016/j.thromres.2015.09.007
Donne, 2002, Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor, Am J Kidney Dis, 40, E22, 10.1053/ajkd.2002.36938
Povey, 2014, Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis, Clin Nephrol, 82, 326, 10.5414/CN107958
Tarshish, 1992, Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone–a report of the International Study of Kidney Disease in Children, Pediatr Nephrol, 6, 123, 10.1007/BF00866289
Licht, 2015, Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, 87, 1061, 10.1038/ki.2014.423
Coppo, 2016, Liver transplantation for aHUS: still needed in the eculizumab era?, Pediatr Nephrol, 31, 759, 10.1007/s00467-015-3278-0
Rabasco, 2015, Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int, 88, 1153, 10.1038/ki.2015.227
Besbas, 2014, A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl, J Nephrol, 27, 457
Bomback, 2012, Eculizumab for dense deposit disease and C3 glomerulonephritis, Clin J Am Soc Nephrol, 7, 748, 10.2215/CJN.12901211
Bonucchi, 2010, [Post-transplant recurrence of glomerulonephritis: a complex clinical case], G Ital Nefrol, 27 Suppl 52, S82
Daina, 2012, Eculizumab in a patient with dense-deposit disease, N Engl J Med, 366, 1161, 10.1056/NEJMc1112273
Garnier, 2014, Successful long-term outcome of kidney transplantation in a patient with X-linked thrombocytopenia: 9-year follow-up, Transplantation, 98, e57, 10.1097/TP.0000000000000338
Gurkan, 2013, Eculizumab and recurrent C3 glomerulonephritis, Pediatr Nephrol, 28, 1975, 10.1007/s00467-013-2503-y
Herlitz, 2012, Pathology after eculizumab in dense deposit disease and C3 GN, J Am Soc Nephrol, 23, 1229, 10.1681/ASN.2011121186
Inman, 2015, Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis, Clin Kidney J, 8, 445, 10.1093/ckj/sfv044
Kerns, 2013, Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy, Pediatr Nephrol, 28, 2227, 10.1007/s00467-013-2565-x
Le Quintrec, 2015, Eculizumab for treatment of rapidly progressive C3 glomerulopathy, Am J Kidney Dis, 65, 484, 10.1053/j.ajkd.2014.09.025
McCaughan, 2012, Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies, Am J Transplant, 12, 1046, 10.1111/j.1600-6143.2011.03923.x
Oosterveld, 2015, Eculizumab in pediatric Dense Deposit Disease, Clin J Am Soc Nephrol, 10, 1773, 10.2215/CJN.01360215
Ozkaya, 2014, Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy, Pediatr Nephrol, 29, 1283, 10.1007/s00467-013-2748-5
Radhakrishnan, 2012, Eculizumab and refractory membranoproliferative glomerulonephritis, N Engl J Med, 366, 1165, 10.1056/NEJMc1106619
Rousset-Rouviere, 2014, Rituximab fails where eculizumab restores renal function in C3nef-related DDD, Pediatr Nephrol, 29, 1107, 10.1007/s00467-013-2711-5
Sanchez-Moreno, 2014, Eculizumab in dense-deposit disease after renal transplantation, Pediatr Nephrol, 29, 2055, 10.1007/s00467-014-2839-y
Vivarelli, 2012, Eculizumab for the treatment of dense-deposit disease, N Engl J Med, 366, 1163, 10.1056/NEJMc1111953
Barbour, 2016, The MEST score provides earlier risk prediction in lgA nephropathy, Kidney Int, 89, 167, 10.1038/ki.2015.322
Cattran, 2009, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, Kidney Int, 76, 534, 10.1038/ki.2009.243
Roberts, 2009, The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Kidney Int, 76, 546, 10.1038/ki.2009.168
Amornsiripanitch, 2010, Complement factor H autoantibodies are associated with early stage NSCLC, Clin Cancer Res, 16, 3226, 10.1158/1078-0432.CCR-10-0321
Dragon-Durey, 2010, Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, 21, 2180, 10.1681/ASN.2010030315
Khandelwal, 2015, Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome, Pediatr Nephrol, 30, 451, 10.1007/s00467-014-2948-7
Sinha, 2014, Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children, Kidney Int, 85, 1151, 10.1038/ki.2013.373
Sheerin, 2016, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, QJM, 109, 27, 10.1093/qjmed/hcv082
Wetzels, 2015, Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome, Am J Kidney Dis, 65, 342, 10.1053/j.ajkd.2014.04.039
Ardissino, 2015, Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update, Am J Kidney Dis, 66, 172, 10.1053/j.ajkd.2015.04.010